Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

India kicks off 'world's largest' vaccination campaign

Published 01/15/2021, 06:39 PM
Updated 01/15/2021, 06:55 PM
© Reuters. FILE PHOTO: A medic fills a syringe with COVAXIN, an Indian government-backed experimental COVID-19 vaccine, before administering it to a health worker during its trials, in Ahmedabad

NEW DELHI (Reuters) - Indian Prime Minister Narendra Modi will launch the "world's largest" vaccination campaign on Saturday as the populous nation tries to bring the COVID-19 pandemic under control starting with two locally-manufactured shots.

Modi will address healthcare workers through video conferencing but will not immediately take the vaccine himself as India is initially prioritising nurses, doctors and others on the front line.

On the first day, around 100 people will be voluntarily vaccinated in each of the 3,006 centres in the country, the government said this week, calling it the start of the biggest such campaign in the world.

"This will be the world’s largest vaccination programme covering the entire length and breadth of the country," Modi's office said in a statement this week.

India, the world's most populous country after China, has said it may not need to vaccinate all of its 1.35 billion people to create herd immunity. Still, covering even half its population will make it one of the largest immunisation programmes in the world, even if countries like the United States were to vaccinate every resident.

Beneficiaries, however, will not be able to choose between the Oxford University/AstraZeneca vaccine and a government-backed, homegrown one from Bharat Biotech whose efficacy is not known. Both are being produced locally.

India, which has reported the highest number of coronavirus infections after the United States, wants to vaccinate around 300 million people with two doses in the first six to eight months of the year.

Some 10.5 million people in India have been infected with the coronavirus, more than 151,000 of whom have died, though the rate of cases has come down since a mid-September peak.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

First to get the vaccine will be 30 million health and other frontline workers, such as those in sanitation and security, followed by about 270 million people older than 50 or deemed high-risk because of pre-existing medical conditions.

Modi, 70, has said politicians will not be considered frontline workers.

On Saturday, he is also expected to formally inaugurate the government's online platform Co-WIN that will provide information on vaccine stocks, storage temperature and keep track of beneficiaries.

The government has already bought 11 million doses of the AstraZeneca (NASDAQ:AZN) COVISHIELD shot, produced by the Serum Institute of India, and 5.5 million of Bharat Biotech's COVAXIN.

COVISHIELD is 72% effective, according to the Indian drug regulator, while Bharat Biotech says COVAXIN's last-stage trial results are expected by March.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.